- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Elutia outlines NXT-41X FDA submission this quarter, targeting Q2 2027 clearance | 1 | Seeking Alpha | ||
| Fr | Elutia reports Q3 results | 1 | Seeking Alpha | ||
| Fr | Elutia Q3 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| Do | Elutia plans Q4 FDA submission for infection-prevention device | 2 | Investing.com | ||
| Do | Elutia plant FDA-Einreichung für infektionshemmende chirurgische Matrix im vierten Quartal | 2 | Investing.com Deutsch | ||
| Do | Elutia Inc.: Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch | 2 | GlobeNewswire (USA) | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 22.10. | Elutia Inc.: Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 | 2 | GlobeNewswire (USA) | ||
| 01.10. | Elutia erhält 8 Millionen US-Dollar aus Treuhandkonto von Boston Scientific | 11 | Investing.com Deutsch | ||
| 01.10. | Elutia receives $8 million escrow from Boston Scientific sale | 4 | Investing.com | ||
| 01.10. | Elutia Inc.: Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 | 366 | GlobeNewswire (Europe) | Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its... ► Artikel lesen | |
| 21.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Elutia Flat on Sale to Cellution | 1 | Baystreet.ca | ||
| 18.08. | Elutia sells SimpliDerm business for up to $11 million | 2 | Investing.com | ||
| 18.08. | Elutia Inc.: Elutia Completes SimpliDerm Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch | 3 | GlobeNewswire (USA) | ||
| 14.08. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.08. | Elutia anticipates NXT-41x clearance in 1H 2027 while targeting >80% gross margins at scale | 1 | Seeking Alpha | ||
| 14.08. | Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch | 1 | Investing.com | ||
| 14.08. | Elutia Q2 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 13.08. | Elutia GAAP EPS of -$0.17 misses by $0.02, revenue of $2.4M misses by $0.5M | 1 | Seeking Alpha | ||
| 13.08. | Elutia sichert sich 26 Mio. USD Kapital vor wichtiger FDA-Entscheidung | 2 | Investing.com Deutsch |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AGIOS | 26,200 | 0,00 % | Truist senkt Kursziel für Agios Pharmaceuticals wegen Bedenken zum Sichelzellprogramm | ||
| ENLIVEX | 1,240 | +8,77 % | Enlivex meldet positive 12-Monats-Daten aus Phase-IIa-Studie zu Kniearthrose | ||
| CARIBOU BIOSCIENCES | 0,442 | 0,00 % | Caribou Biosciences, Inc. - 8-K, Current Report | ||
| BOLT BIOTHERAPEUTICS | 6,510 | -0,46 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 2,770 | +2,03 % | bioAffinity Technologies GAAP EPS of -$5.89, revenue of $1.1M | ||
| FIRST TRACKS BIOTHERAPEUTICS | 40,850 | -5,88 % | Guggenheim raises First Tracks stock price target to $110 on celiac data | ||
| TELA BIO | 0,823 | +0,41 % | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARRIVENT BIOPHARMA | 13,650 | +0,07 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| SURROZEN | 30,810 | -0,61 % | Surrozen, Inc.: Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema | First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 1,850 | -1,07 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen | |
| QIAGEN | 45,205 | -0,14 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| CG ONCOLOGY | 75,93 | 0,00 % | Kurssprung bei CG Oncology: Starke Quartalszahlen und Pipeline-Katalysatoren treiben die Aktie an | ||
| COGENT BIOSCIENCES | 31,645 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| EDGEWISE THERAPEUTICS | 45,030 | -0,02 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| MODERNA | 227,50 | -0,11 % | Halten Zahlen den Crash auf: Apple, Palantir, AMD & Moderna: Wall Street vor explosiver Earnings-Woche! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW45) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,835 Euro und damit -0,29 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.